argenx R&D Day on July 16
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that it will host an R&D day on Tuesday, July 16, 2024 at 8:30am ET in New York City to unveil its ‘Vision 2030:Taking Breakthrough Science to 50,000 Patients’ and provide updates from across its current and future clinical pipeline.
- R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development
- Next wave of innovative pipeline candidates to be introduced highlighting long-term commitment to transform autoimmunity
- Decision to not advance development of efgartigimod in PC-POTS based on Phase 2 ALPHA data
- Information will be shared leading up to the R&D Day on the event website at https://argenx2024rdday.q4ir.com, including the agenda, supporting materials, and a link to the live audio webcast. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for 90 days.
- https://www.biospace.com/argenx-to-unveil-its-vision-2030-taking-breakthrough-science-to-50-000-patients-during-its-upcoming-r-and-d-day-on-july-16-2024
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.